Clinical Trials Browser

Approved for marketing × OTHER × Gemtuzumab × Clear all

NCT01869803 2018-03-02

Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia

Approved for marketing

Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute